Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The OPA1 pre-mRNA is the unspliced transcript of the **Optic atrophy 1 gene (OPA1)**, encoding the mitochondrial dynamin-like GTPase critical for mitochondrial inner membrane fusion, cristae architecture, and apoptotic regulation. The OPA1 gene undergoes complex alternative splicing, producing eight different mRNA isoforms, which give rise to long and short protein forms essential for mitochondrial function. Pathogenic variants in the gene, including those affecting splicing of the pre-mRNA, can lead to dominant optic atrophy and syndromic forms (DOA+), often through haploinsufficiency or dominant-negative mechanisms[6][7][8]. OPA1 pre-mRNA itself is not a direct drug target but is of high research interest for its role in disease mechanisms and potential as a biomarker.
Modulation of splicing could change OPA1 isoform ratio, potentially affecting disease outcomes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Optic atrophy 1 pre-mRNA (pre-mRNA transcript of the Optic atrophy 1 gene) (OPA1 pre-mRNA).